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Background: Information on Streptococcus pneumoniae nasopharyngeal (NP) carriage before the pneumo-
coccal conjugate vaccine (PCV) introduction is essential to monitor impact. The 10-valent PCV (PCV10)
was officially introduced throughout Ugandan national childhood immunization programs in 2013 and
rolled-out countrywide during 2014. We aimed to measure the age-specific Streptococcus pneumoniae
carriage and serotype distribution across all population age groups in the pre-PCV10 era in South
Western Uganda.
Methods: We conducted a two-stage cluster, age-stratified, cross-sectional community-based study in
Sheema North sub-district between January and March 2014. One NP swab was collected and analyzed
for each participant in accordance with World Health Organization guidelines.
Results: NP carriage of any pneumococcal serotype was higher among children <2 years old (77%;
n = 387) than among participants aged 15 years (8.5%; n = 325) (chi2 p < 0.001).
Results: Of the 623 positive cultures, we identified 49 serotypes among 610 (97.9%) isolates; thirteen
(2.1%) isolates were non-typeable. Among <2 years old, serotypes 6A, 6B, 14, 15B, 19F and 23F accounted
for half of all carriers. Carriage prevalence with PCV10 serotypes was 29.4% among individuals aged
<2 years (n = 387), 23.4% in children aged 2–4 years (n = 217), 11.4% in 5–14 years (n = 417), and 0.4%
among individuals 15 years of age (n = 325). The proportion of carried pneumococci serotypes con-
tained in PCV10 was 38.1% (n = 291), 32.8% (n = 154), 29.4% (n = 156), and 4.4% (n = 22) among carriers
aged <2 years, 2–4 years, 5–14 years and 15 years, respectively.
Discussion: In Sheema district, the proportion of PCV10 serotypes was low (<40%), across all age groups,
especially among individuals aged 15 years or older (<5%). PCV10 introduction is likely to impact trans-
mission among children and to older individuals, but less likely to substantially modify pneumococcal NP
ecology among individuals aged 15 years or older.
 2017 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).
1. Introduction
Streptococcus pneumoniae is a leading cause of morbidity
and mortality, particularly in young children, especially in
low-income settings [1]. The human nasopharynx (NP) is the main
reservoir of person-to-person transmission of pneumococci.
Nasopharyngeal colonization is very common, usually asymp-
tomatic, but may sometimes lead to the development of pneumo-
coccal disease [2,3].
Pneumococcal conjugate vaccines (PCVs), targeting 10 (PCV10)
and 13 (PCV13) pneumococcal serotypes, are steadily being intro-
duced throughout African national childhood immunization pro-
grams. Introduction of PCVs is expected to reduce the incidence
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of severe pneumococcal diseases and to reduce, or eliminate, NP
carriage with vaccine-type (VT) pneumococci. By reducing car-
riage, PCV reduces transmission and therefore confers indirect pro-
tection more widely across the entire population [4]. While
serotypes not targeted by the vaccine tend to replace eliminated
VT pneumococci in the NP following PCV introduction [5], overall
net reductions in the burden of invasive pneumococcal disease
(IPD) have been observed [6–8]. However, the impact of PCV on
IPD tends to vary across countries and settings [8], notably due
to differences in the epidemiology of NP carriage and circulating
serotypes. Studying nasopharyngeal carriage across all age groups
is critical to monitor the indirect impact of PCV among the entire
population [4,9] and to predict the impact on disease through
transmission dynamic models. Where the collection of high-
quality IPD incidence data is impracticable, carriage studies pro-
vide a valid alternative to assess the population impact of PCV
introduction [10,11].
In Uganda, PCV10 was introduced officially in April 2013 and
rolled-out countrywide during 2014 [12]. PCV10 includes sero-
types 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. Previous NP carriage
studies conducted in Uganda were restricted to specific risk groups
(HIV positive adults [13]; children with sickle cell disease [14],
children attending routine outpatient consultation [15], or children
younger than 5 years living in rural villages of East Uganda [16,17].
To our knowledge, there has been no previous evaluation of pneu-
mococcal carriage and serotype distribution across all age groups
in Uganda prior to vaccine introduction. Therefore, we conducted
a community-based study in Sheema district (South Western
Uganda) to measure the age-specific prevalence and serotype dis-
tribution of pneumococcal carriage in the pre-PCV10 period and to
provide a benchmark against which findings from the post-PCV10
period can be compared.
2. Material and methods
2.1. Study setting and target population
The study was conducted between January 22 and March 15,
2014 in four rural sub-counties (Kibingo/Sheema town council,
Kabwohe-Itendero town council, Kagango and Kigarama) of
Sheema North sub-district, located in the south of the Western
region of Uganda. The area included 215 rural villages and two
small towns (Kabwohe and Itendero) with a total of 76,804 inhab-
itants [18]. In Uganda there are two dry seasons between Decem-
ber to February and June to August. The Uganda National Expanded
Program on Immunization (UNEPI) recommends three primary
doses of PCV10, given at 6, 10 and 14 weeks of age (i.e. ‘3 + 0’
schedule). However, at the time of the study, PCV10 had not yet
been introduced in Sheema district. Although PCV10 was intro-
duced officially in Uganda, PCV13 might also become available
subject to out-of-pocket payment in private health services.
2.2. Sample size and study design
This was a cross-sectional population-based study using two-
stage cluster sampling. The sample size calculations were stratified
by age group and based on an expected carriage prevalence of 70%
in children aged <5 years, 35% among those aged 5–14 years and
15% among those aged 15 years [19–21]. Accounting for a preci-
sion of 5%, a design effect of 1.5 and a 10% non-response (refusal or
difficulties in processing NP swabs), the target sample size
included 538 children aged <2 years, 538 children aged <5 years,
583 children aged 5–14 years, and 327 individuals aged 15 years.
Considering that children <2 years old represent 40% of the chil-
dren <5 years old, we aimed to recruit 538 children aged <2 years
and 323 (0.6 ⁄ 538) children aged 2–4 years, i.e. 1771 individuals
in total.
We randomly selected 60 clusters from the exhaustive list of
villages and town districts, with a probability proportional to their
population size. Within each cluster, we randomly selected 30
households from a household census conducted by the village’s
health teams and authorities and a specific sample size was tar-
geted in each age group. We only selected one individual within
each household to limit intra-household clustering. Where
selected individuals were absent, two other attempts were made
to contact them (one the same day and, if unsuccessful, the next
Saturday).
2.3. Data collection
For each participant, study teams collected information on gen-
der, age, household size and composition, history of oral antibiotic
treatment and respiratory symptoms (cough, runny nose/ sneez-
ing, difficulties breathing, sore throat, otitis) in the two weeks pre-
ceding the study.
One NP sample was obtained by experienced nurses from the
posterior pharynx of each study participant using a flexible,
pediatric-size or adult-size flocked nylon swab (Copan Diagnostics,
USA) in accordance with World Health Organization (WHO) guide-
lines [22].
2.4. Laboratory analysis
The NP samples were transported and analyzed according to
WHO guidelines [22]. Once collected, NP swabs were inoculated
in a skim milk-tryptone-glucose-glycerin (STGG) medium, trans-
ported at +4 C in cool boxes and frozen at the Epicentre laboratory
in Mbarara (30 min drive from Sheema district) at 20 C within
eight hours of collection. After vortexing the sample, 50-mL was
inoculated onto a selective agar plate of five mg/L gentamicin-
Columbia agar with 5% sheep blood and incubated overnight at
37 C in 5% CO2. One colony from the most predominant typical
pneumococcal morphology was selected and tested for optochin
susceptibility. In case of growth inhibitory zone between seven
and 13 mm in diameter, bile solubility was used to confirm pneu-
mococcal identification. Pure pneumococcal isolates were stored at
80 C in STGG until shipment under negative cold chain to the
laboratory of the KEMRI-Wellcome Trust Research Programme, Kil-
ifi, Kenya, for serotyping. There, pneumococcal isolates were first
tested by latex agglutination and then serotyped by the Quellung
reaction, using polyclonal rabbit antisera (Statens Serum Institut,
Copenhagen, Denmark). The strains with inconclusive serotyping
by Quellung reaction were tested by polymerase chain reaction
(PCR) targeting the genes encoding autolysin (lytA). If lytA-
positive, the isolates were then subjected to sequential multiplex
PCR to deduce capsular type [23]. We performed internal quality
control of STGG, gentamicin blood agar to ensure sterility and
the ability to support pneumococcal growth. Serotyping was mon-
itored by a twice-monthly internal quality assurance scheme,
using pneumococcal reference strains. Additionally, 10% of all ser-
otyped isolates were randomly selected and tested by multiplex
PCR as Quellung reaction quality control.
2.5. Data analysis
Data were double-entered using Voozanoo (www.voozanoo.net,
Epiconcept, Paris, France). To adjust for clustering, standard errors
were computed by using the linearized variance estimator. To
account for the unequal intra-household sampling probabilities,
analyses were weighted on the household size. Reported propor-
tions are weighted unless otherwise specified. Results combining
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all age strata were also weighted to account for the age-stratified
design. The prevalence of NP carriage with S. pneumoniae is pre-
sented with their associated 95% confidence intervals (95%CI).
Associations between S. pneumoniae NP carriage and participant
characteristics (sex, history of oral antibiotic treatment and respi-
ratory symptoms) were analyzed by logistic regression, adjusting
for age group (<2 years; 2–4 years; 5–14 years; 15 years). Data
analysis was conducted using STATA version 13 (Stata Corporation,
College Station, Texas, USA).
2.6. Ethics
Ethical clearance was obtained from the Ethical review board
of Médecins Sans Frontières, the Faculty of Medicine Research &
Ethics Committee of the Mbarara University of Science and Tech-
nology (MUST), the MUST – Research and Ethics Committee, the
Uganda National Council for Science and Technology and the
London School of Hygiene and Tropical Medicine. All participants
(or caregivers for individuals younger than 18 years of age) pro-
vided written informed consent before participation. In addition,
children (from 8 to 17 years old) provided assent prior to
participation.
3. Results
3.1. Study population
From 1771 randomly selected households, individuals from 67
(3.8%) households refused to participate, 156 (8.8%) could not be
contacted after two visits, and 202 (11.4%) did not meet the sam-
pling age requirements. In total, 1346 households participated in
the study, including 387 children <2 years old, 217 aged 2–4 years
old, 417 aged 5–14 years old and 325 aged 15 years old. These
represented, respectively, 72%, 67%, 72% and 99% of the targeted
samples. The median household size was 5 (range 1–18) with a
median of two individuals younger than 15 years old per house-
hold (range 0–11). Overall, 698 (56.3%, weighted on the household
size and to account for the age-stratified design) participants were
female. Respectively, 168 (12.2%, weighted) and 182 (12.8%,
weighted) of the participants reported oral antibiotic intake and
respiratory symptoms in the two weeks preceding the study
(Table 1).
3.2. Carriage prevalence and serotype distribution
Of the 1346 NP swab collected, 626 suspected S. pneumoniae
were isolated on culture, but three were not confirmed as S.
pneumoniae by PCR lytA, leaving 623 positive samples. NP car-
riage prevalence was higher among children <2 years old
(77.0%) than among participants aged 15 years old (8.5%) for
any pneumococcal serotype (chi2 p < 0.001) (Table 1). Carriage
prevalence with PCV10 serotypes was 29.4%, 23.4%, 11.4%, and
0.4% among individuals aged <2 years (n = 387), 2–4 years
(n = 217), 5–14 years (n = 417) and 15 years (n = 325), respec-
tively (Table 1).
We identified 49 serotypes among 610 (97.9%) isolates, of
which 17 could be serotyped only by multiplex PCR. Thirteen
(2.1%) isolates were non-typeable (Table 2). Of 63 randomly
selected isolates tested by multiplex PCR as Quellung reaction
quality control, 10 isolates were of serotypes not available for con-
firmation under the PCR schema. Of the 53 remaining isolates, we
observed 100% concordance between the serotypes identified by
Quellung reaction and by PCR.
The age-specific serotype distributions are presented in Fig. 1.
Among participants <2 years old, six serotypes (6A, 6B, 14, 15B, Ta
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19F and 23F) accounted for 50.1% of the carriers. NP carriage preva-
lence and serotype distributions across six age groups are pre-
sented in the supplementary material.
Of all carried pneumococci, PCV10 serotypes (identified by
either Quellung reaction or PCR) among carriers <2 years old were
38.1% (n = 291, 95% CI 31.8–44.9), 32.8% (n = 154, 95% CI 25.5–
41.0) among carriers 2–4 years old, 29.4% (n = 156, 95% CI 22.2–
37.9) among carriers 5–14 years old and 4.4% (n = 22, 95% CI 0.5–
29.7) among older carriers (p=0.011). Considering PCV13 sero-
types, these proportions were 54.3% (n = 291, 95% CI 47.9–60.5),
48.2% (n = 154, 95% CI 40.4–56.1), 43.4% (n = 156, 95% CI 34.9–
52.2) and 15% (n = 22, 95% CI 3.9–43.4) (p = 0.007).
There was no difference in NP carriage of S. pneumoniae for
female gender (crude OR 0.69, 95% CI 0.54–0.87; weighted and
age-adjusted OR 0.83, 95% CI 0.63–1.09), history of oral antibi-
otic treatment (crude OR 1.16, 95% CI 0.83–1.61; weighted and
age-adjusted OR 1.09; 95% CI 0.68–1.76) or respiratory symp-
toms (crude OR 1.41, 95% CI 1.01–1.96; weighted and age-
adjusted OR 1.17; 95% CI 0.77–1.77) in the previous two
weeks.
4. Discussion
This is the largest community-based study reporting S. pneumo-
niae NP carriage and serotype distribution across all population age
groups in the pre-PCV era in Uganda. Studies of a similar size have
been conducted in Kenya [19,24,25], but not elsewhere in East
Africa.
An estimated 70% of children under 5 years old carried S. pneu-
moniae, which is slightly higher than the 56% pneumococcal carri-
ers reported among 1723 children under 5 years old in a rural
community of Eastern Uganda, mostly during the dry season from
2008 to 2011 [16,17]. However, this is consistent with the
community-based estimations from large Kenyan carriage studies
[20,24]. In a meta-analysis pooling pre-vaccine data from low
income countries (including Kenya, Tanzania, The Gambia, and
Bangladesh) [26], carriage prevalence in healthy children under
5 years old was estimated at 64.8% (95% CI: 49.8%–76.1%) with sub-
stantial heterogeneity from 35% in Tanzania [27] to over 90% in the
Gambia [28]. Besides the methodological differences across stud-
ies, variations in carriage estimates may result from differences
in climates and season [20,25], burden of underlying immunosup-
pression [20], crowding or social mixing patterns influencing
transmission.
We found no evidence of a difference in pneumococcal carriage
prevalence according to gender, recent respiratory symptoms or
antibiotic intake. However, this study was not designed to capture
differences according to environmental or individual factors. By
sampling participants over a large rural and semi-urban area, we
intended to capture the overall carriage characteristics in the com-
munity, thereby providing an important baseline for post-PCV
impact assessments.
The most frequent serotypes found in the present study were
comparable to those previously reported in carriage studies in sev-
eral African countries [26] and, with the exception of the serotype
29 that was less frequent in our study, in children of East Uganda
(19F, 23F, 6A, 29, and 6B) [16]. In Sheema district, the proportions
of serotypes included in PCV10 or PCV13 were low. We found that
only 38.1% of all isolates were included in PCV10 among children
under 2 years old and 32.8% among children aged 2–4 years, simi-
lar to studies in Kenya and Tanzania where 42–56% of serotypes
carried by unvaccinated children under 5 years old were included
in the PCV10 [20,24,27]. Estimations reported from East Uganda
[16] were comparable, with only half of the circulating pneumo-
coccal serotypes among children under 5 years old covered by
available PCVs (42% for PCV10 and 54% for PCV13). However, both
in East Uganda [16] and in Sheema, the NP carriage of serotypes 1
and 5 was rare, possibly as a result of their short duration or low
carriage density [29]. If these serotypes are substantial causes of
IPD in Uganda as they are overall in Africa [30], carriage studies
might be of limited value to assess the impact of PCV on their
related disease burden in this setting.
Children remain the key drivers of S. pneumoniae transmission,
and consequently, have long been the focus of carriage studies.
However, modelling of PCV impact requires information on car-
riage prevalence (and ideally contacts and transmission probabili-
ties) for all age groups – not just the vaccinated age group. Our
study is the first to report carriage and serotype distribution
among Ugandan adults from the general population prior to vac-
cine introduction. As expected, age appears as a major determinant
of carriage prevalence. We observed lower pneumococcal carriage
prevalence among older individuals, with half of the prevalence
among those aged older than 5 years. S. pneumoniae carriage
prevalence was about 9% among those aged 15 years, similar to
previous observations among Kenyan adults, i.e. around 10%
[19,25] and around 20% [24]. The proportion of PCV10 serotypes
among carriers was also lower among older individuals,
Table 2
Serotype distribution, Sheema North Sub District, Uganda, January–March 2014
(n = 623).
Serotype (n) <2 years 2–4 years 5–14 years 15 years Total
6B* 34 14 11 0 59
6A** 32 14 7 0 53
19F* 35 10 8 0 53
14* 26 8 6 0 40
23F* 14 8 9 0 31
13 12 9 5 3 29
15A 11 11 6 1 29
19A** 11 6 3 1 21
3** 4 4 12 1 21
15B 13 3 4 1 21
21 8 4 7 1 20
34 8 6 4 2 20
11A 4 8 7 0 19
35B 9 3 5 0 17
16F 5 3 8 1 17
19B 8 2 6 0 16
Non-typeable 5 2 5 1 13
35A 6 2 3 2 13
4* 5 4 4 0 13
10A 6 4 1 1 12
15C 10 1 1 0 12
29 4 0 6 0 10
23B 4 1 2 1 8
9V* 2 3 2 0 7
7C 1 2 3 0 6
20 3 3 0 0 6
18F 2 2 0 1 5
9L 1 1 1 2 5
17F 1 1 3 0 5
28F 0 1 3 0 4
5* 1 1 1 1 4
12F 0 2 1 0 3
6C 1 1 1 0 3
7F* 0 1 2 0 3
22F 1 1 1 0 3
33B 1 0 0 1 2
1* 0 0 2 0 2
38 0 1 1 0 2
23A 1 1 0 0 2
18C* 0 1 1 0 2
22A 0 2 0 0 2
24F 1 1 0 0 2
Others 1 2 4 1 8
One serotype 16F, one serotype 20, one serotype 34 and fourteen serotypes 14 could
be serotyped by PCR only.
* Serotypes included in PCV10 (1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F).
** Additional serotypes included in PCV13 (3, 6A, and 19A).
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representing less than a third of all isolates in participants aged 5–
14 years and, although estimated in a relatively small sample, less
than 5% of all isolates among participants aged 15 years.
The prevalence and distribution of circulating serotypes not
included in PCV10, as well as their level of invasiveness, will be
key determinants of the overall impact of the vaccine on disease,
given that serotype replacement is likely. Included in PCV13 but
not in PCV10, serotype 6A was a major circulating serotype in chil-
dren under 5 years old in Sheema. This serotype is known as a
major cause of childhood IPD in Africa [30] and was the second
most frequent serotype identified in a series of 30 children under
5 years old with pneumococcal meningitis in Uganda (after sero-
type 6B and before serotypes 22A, 23F 14 and 19A) [31]. In this ser-
ies, 46% of S. pneumoniae meningitis were due to serotypes
included in PCV10 and 70% in PCV13. Serotypes 19A and 3 are also
known causes of IPD [30] and are covered by PCV13 but not PCV10;
they were found across all age groups. Other non-vaccine sero-
types represented a high proportion of the circulating serotypes
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Fig. 1. Age-specific serotype NP carriage prevalence. Sheema North Sub District, Uganda, Jan–March 2014. Black = PCV10 serotypes; Grey = PCV13 additional serotypes;
White = Non vaccine serotypes; NT = Non-Typeable; NP = Nasopharyngeal; Carriage prevalence are weighted on the household size.
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in Sheema and they deserve post-PCV monitoring as they are
potential candidates for serotype replacement disease in the
post-PCV era. For example, serogroup 15 and serotype 35B were
relatively frequent in Sheema district and they have emerged
among IPD and other pneumococcal diseases in the post-PCV era
in several high-income countries [32–35].
Non-vaccine serotypes of low prevalence in the pre-PCV era
might also unexpectedly increase in the post-PCV era. Notably, ser-
otype 6C has emerged in several parts of the world after PCV intro-
duction [37] and it became the most common serotype carried by
Brazilian children three to four years after the introduction of the
PCV10 in the country [36–37]. Although reported of low invasive
potential [38], its association with multidrug resistance raises a
concern [37]. In Brazil, baseline serotypes were similar to Sheema
(6B, 19F, 6A, 14, and 23F [36]) and, after routine PCV10 use, there
was a clear impact of PCV10 by reducing the NP carriage with
PCV10 serotypes [36–37]. Prevalence of carriage of serotypes 6A
and 19A remained unchanged but, in addition to the serotype 6C,
there was an increase in serotypes 15A, 15B, 15C, and 11A [36–
37]. While knowledge is accumulating on the disease potential of
non-vaccine serotypes, carriage studies should ideally be repeated
to follow changes in serotype-specific prevalence. How these
would actually translate into changes in the serotype-specific
pneumococcal disease incidence remains unclear, as little replace-
ment in disease has been reported after complete replacement in
carriage [26].
We could not measure the density of carriage at the time of the
study. Also, we did not assess multiple or co-carriage nor sensitiv-
ity to antimicrobial agents, reported as an increasing concern
worldwide, including Uganda [15,17]. Despite these limitations,
our results provide important information to monitor changes that
will result from PCV10 introduction in Sheema district. They also
underline that the proportion of serotypes included in PCV10s
was low (<40%), across all age groups, especially among individuals
aged 15 years (<5%). Introduction of PCV10 is thus likely to
impact transmission among children and to older individuals, but
less likely to substantially modify pneumococcal NP ecology
among individuals aged 15 years in this area of Uganda.
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